| Ticker |
ICPT
|
| CIK | 0001270073 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 305 MADISON AVENUE, MORRISTOWN, NJ, 07960 |
| Website | interceptpharma.com |
| Phone | 646-747-1000 |
| CEO | Jerome B. Durso |
| Employees | 440 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
ABC Farmaceutici, and Alkem Laboratories are Key Players in the Global Primary Biliary Cholangitis Therapeutics MarketPrimary Biliary Cholangitis Therapeutics Market. The primary biliary cholangitis therapeutics market size was valued at $683.95 million in 2022, and is estimated to reach $1.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032. "-- Allied Market Research. WILMINGTON, DELAWARE, UNITED STATES, April 5, 2024/ EINPresswire.com/-- Allied Market Research... ABC Farmaceutici, and Alkem Laboratories are Key Players in the Global Primary Biliary Cholangitis Therapeutics MarketPrimary Biliary Cholangitis Therapeutics Market. The primary biliary cholangitis therapeutics market size was valued at $683.95 million in 2022, and is estimated to reach $1.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032. "-- Allied Market Research. WILMINGTON, DELAWARE, UNITED STATES, April 5, 2024/ EINPresswire.com/-- Allied Market Research... Nonalcoholic Steatohepatitis Market Analysis 2032: Epidemiology, Therapies, FDA Approvals and Companies by DelveInsightNonalcoholic Steatohepatitis companies are Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly, Madrigal Pharmaceuticals, Terns, and more.. Key facts of the Nonalcoholic Steatohepatitis Market Report are:• According to DelveInsight, Nonalcoholic Steatohepatitis market size is expected to grow at a decent CAGR by 2032.• Leading Nonalcoholic... Nonalcoholic Steatohepatitis Market Analysis 2032: Epidemiology, Therapies, FDA Approvals and Companies by DelveInsightNonalcoholic Steatohepatitis companies are Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly, Madrigal Pharmaceuticals, Terns, and more.. Key facts of the Nonalcoholic Steatohepatitis Market Report are:• According to DelveInsight, Nonalcoholic Steatohepatitis market size is expected to grow at a decent CAGR by 2032.• Leading Nonalcoholic... Nonalcoholic Steatohepatitis Market Analysis 2032: Epidemiology, Therapies, FDA Approvals and Companies by DelveInsightNonalcoholic Steatohepatitis companies are Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly, Madrigal Pharmaceuticals, Terns, and more.. Key facts of the Nonalcoholic Steatohepatitis Market Report are:• According to DelveInsight, Nonalcoholic Steatohepatitis market size is expected to grow at a decent CAGR by 2032.• Leading Nonalcoholic... |
